ArticleJournal of Indian Association of Pediatric Surgeons
Meso-Rex Bypass: Insights from a Single-center Experience in India.
Article in Journal of Indian Association of Pediatric Surgeons. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The Meso-Rex bypass (MRB) provides a physiological cure for EHPVO by restoring hepatopetal flow, effectively reducing portal pressure. We share our experience with the MRB procedure, its outcomes, and challenges. Aim: To describe the feasibility and effectiveness of MRB in children with EHPVO in our practice. Materials and Methods: This is a retrospective study of children with EHPVO who underwent MRB between January 2013 and May 2024. MRB was considered in patients with asymptomatic splenomegaly, moderate hypersplenism, and patent left portal vein either on Doppler or contrast-enhanced computed tomography. The internal jugular vein was used in all cases as jump graft. At follow-up, Doppler was done to note the patency of the shunt and size of the spleen. Results: Eighty-two shunts of all types were performed. MRB was considered in 17 patients (21%) as per preoperative criteria. MRB was possible in only 10 (12%). Data were analyzed for these 10 children. The average age was 4.5 years (range 1-11 years), 7 were <5 years. Presentation included hematemesis (eight children) and splenomegaly (two children). Four had moderate hypersplenism. Two developed transient self-limiting ascites in early postoperative period. There were no other immediate perioperative complications. The average duration of follow-up was 67 months. One child had hematemesis 2 years after surgery due to stenosis at the proximal end of graft which was treated with endovascular dilatation. Hypersplenism resolved in all children. Conclusion: MRB is the only curative option for EHPVO. It is feasible in a small subset of patients. Outcomes of MRB are good, especially in younger children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.